body { -ms-overflow-style: scrollbar; overflow-y: scroll; overscroll-behavior-y: none; } .errorContainer { background-color: #FFF; color: #0F1419; max-width: 600px; margin: 0 auto; padding: 10%; font-family: Helvetica, sans-serif; font-size: 16px; } .errorButton { margin: 3em 0; } .errorButton a { background: #1DA1F2; border-radius: 2.5em; color: white; padding: 1em 2em; text-decoration: none; } .errorButton a:hover, .errorButton a:focus { background: rgb(26, 145, 218); } .errorFooter { color: #657786; font-size: 80%; line-height: 1.5; padding: 1em 0; } .errorFooter a, .errorFooter a:visited { color: #657786; text-decoration: none; padding-right: 1em; } .errorFooter a:hover, .errorFooter a:active { text-decoration: underline; } #placeholder, #react-root { display: none !important; } body { background-color: #FFF !important; }

JavaScript is not available.

We’ve detected that JavaScript is disabled in this browser. Please enable JavaScript or switch to a supported browser to continue using twitter.com. You can see a list of supported browsers in our Help Center.

Terms of Service Privacy Policy Cookie Policy Imprint Ads info © 2023 Twitter, Inc.

Conversation

Did you know the lead pain drug at Centrexion, led by ex-Pfizer CEO Jeff Kindler, failed 2 Phase III studies in 2020? Probably not because the company never disclosed it — until recently, as

reports, and only discreetly on clinicaltrials.gov Story:

Quote Tweet

Centrexion's knee pain drug failed 2 late-stage studies, but "potential goal" is still to ask FDA for approval. Studies concluded 22 & 29 months ago. Led by former Pfizer CEO Jeff Kindler, the biotech never planned to issue a press release on the studies endpts.com/exclusive-cent

2:50 PM · Apr 29, 2022

Replying to

and

I misread this as "lead paint drug" at first and was immediately interested

Replying to

and

Well you never know with the FDA neuro division….

The_Skeptical_Scientist

@TheSkepticalSc2

Replying to

and

Aduhelm 2.0 Electric Boogaloo!

Replying to

and

No, and nobody cares. They can ask whatever they want, doesn’t mean they’ll get it. Write about something useful, instead of retweeting a dumb article.